Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension
Status:
Withdrawn
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
Study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-251
administered for 24 weeks in participants with pulmonary arterial hypertension (PAH)